Early access programs (EAPs) act as a bridge to successful commercialization. This webinar will focus on the ways EAPs engage stakeholders and foster advocacy among patient organizations, Physicians and key opinion leaders.The session will help gain insights into the best time in clinical development to prepare for launch and the importance of adopting transitional thinking from clinical development to commercial launch.
During this webinar, the attendees will get to explore the role of EAPs in gathering real-world data and the potential to generate revenue within certain markets. The featured speaker will share insights into EAPs and their impact on EU commercialization.
Also, the session will help attendees navigate the real challenges faced in weaving EAPs into commercial strategies, as well as understand the complexities around managing cost, small patient populations in rare diseases, resource allocation and navigating the intricacies of European regulation.
The attendees will also gain practical considerations for crafting a strong EAP strategy and understand the importance of:
- Starting early
- Starting with the end in mind
- Engaging with key stakeholders early
During the webinar, the attendees can directly engage with the experts, ask their burning questions and receive personalized insights to navigate the challenges they are facing in implementing EAPs in their European commercialization strategy.
Register now to gain insights into how EAPs act as a bridge to successful commercialization in the EU market.
Speaker
Heather Masters, VP Global Pricing & Market Access, WEP Clinical
Heather Masters is responsible for Market Access at WEP Clinical and works with our partners to secure optimal pricing, access and reimbursement of licenced portfolios. Heather has been a successful business leader in the pharmaceutical industry for nearly 20 years and has extensive knowledge of global healthcare systems and expertise in developing market access strategies for innovative therapies in oncology and rare diseases. Heather has held a number of senior management roles in Commercial Marketing & Market Access for Novartis AG and has worked as a Business Consultant with various biopharmaceutical companies across a wide range of therapy areas.
Message PresenterWho Should Attend?
This webinar will especially appeal to global pharma and biotech companies with drug candidates in Phase II/III trials in areas of rare disease, oncology and cell and gene therapy. Attendees involved in the following can also attend this webinar:
- Pricing, reimbursement, market access leads
- Commercial operations
- Clinical development/operations
- Regulatory affairs
- HEOR
- Medical affairs
- Business strategy and development
- Patient advocacy leads
What You Will Learn
- Gain practical insights on early access programs (EAPs) in European commercialization
- Learn to navigate challenges, utilize EAPs as a bridge to successful commercialization
- Build a strong strategy that includes early stakeholder engagement and transitional thinking
Xtalks Partner
WEP Clinical
WEP Market Access specialises in providing strategic consulting for transition from clinical development to commercialization of Rare disease, Oncology, and Advanced therapies, focusing on maximizing patient impact. As a leader in treatment access solutions, WEP Clinical partners with Sponsors and CROs to expand access to promising medicines globally. We support companies through every phase of drug development and commercialization, enhancing value from product approval, through launch, and beyond.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account